Who Paid My Doc
Eugen Ivan
Lawton, OK Medical Doctor
NPI 1790735389 CMS profile 126150
3106 Nw Arlington Ave, Lawton, OK 73505
General payments
$32,982
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,600
Through program year 2025, Eugen Ivan of Lawton, OK is reported in the CMS Open Payments database as having received $32,982 across 100 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,600 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $490 | 19 | |
| 2024 | General | $391 | 14 | |
| 2023 | General | $2,566 | 8 | |
| 2021 | General | $8,441 | 20 | |
| 2020 | General | $5,961 | 5 | |
| 2019 | General | $15,133 | 34 |
Beside peers
- Eugen Ivan
- Oklahoma median
- Middle half of Oklahoma
- National median
In program year 2025, general payments to Eugen Ivan were reported at $490. Among 11,599 Oklahoma profiles paid that year, the median was $171 and the middle half received between $51 and $608.
Show as a table
| Year | Eugen Ivan | Oklahoma median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $15,133 | $175 | $48–$674 | $163 |
| 2020 | $5,961 | $117 | $34–$396 | $114 |
| 2021 | $8,441 | $133 | $34–$473 | $132 |
| 2022 | $0 | $153 | $43–$574 | $149 |
| 2023 | $2,566 | $166 | $45–$588 | $160 |
| 2024 | $391 | $170 | $48–$602 | $164 |
| 2025 | $490 | $171 | $51–$608 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 31 drugsPart D claims
1,703
Drug cost
$408,523
Branded share of claims
38.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 219 | $233,838 | |
| Entresto Sacubitril/Valsartan | Brand | 74 | $86,343 | |
| Xarelto Rivaroxaban | Brand | 36 | $41,011 | |
| Multaq Dronedarone Hcl | Brand | 13 | $14,275 | |
| Repatha Pushtronex Evolocumab | Brand | 11 | $9,857 | |
| Repatha Syringe Evolocumab | Brand | 11 | $3,036 | |
| Atorvastatin Calcium | Generic | 227 | $3,031 | |
| Metoprolol Succinate | Generic | 115 | $2,288 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 126 | $1,924 | |
| Potassium Chloride | Generic | 47 | $1,555 |
The 10 drugs with the highest cost, of 31 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 92 billing codesPaid by Medicare
$179,819
Medicare patients
1,726
Services billed
4,229
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 56% | |
| Ischemic heart disease | 52% | |
| Diabetes | 48% | |
| Heart failure | 43% | |
| Chronic kidney disease | 37% | |
| Atrial fibrillation | 35% | |
| COPD | 35% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
100 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.